文献速递眼底病与葡萄膜炎

TREX-AMD试验中雷珠单抗治疗眼黄斑萎缩与脉络膜新生血管的地形对应关系

Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial.
PubMed 文献 · Am J Ophthalmol · 2018-05-12

该研究为TREX-AMD随机对照试验的事后分析,纳入60例未经治疗的新生血管性年龄相关性黄斑变性患者,随访18个月,评估基线脉络膜新生血管(CNV)与随访时黄斑萎缩(MA)的地形对应关系。结果显示多数MA病变位于基线CNV区域内,而非CNV区域外,基线MA也倾向于位于CNV区域内。

要点

  • 26眼在18个月时有MA且基线有CNV,其中84.6%眼显示MA与CNV重叠。
  • MA出现在对应基线经典CNV区域者占36.4%,隐秘CNV区域者占40.9%,两者均有着占22.7%。
  • 基线MA位于经典CNV区域者占76.9%,隐秘CNV区域者占61.5%,两者均有者占15.4%。

核心结论

  • 在雷珠单抗治疗的NVAMD眼中,更多MA病变位于基线CNV区域内(1型,CNV相关MA)而非区域外(2型,CNV无关MA)。
  • 基线MA在治疗前阶段也倾向于位于CNV区域内。

研究设计与样本

  • TREX-AMD随机对照临床试验数据的事后分析,纳入60例未经治疗的NVAMD患者,随访18个月。
  • MA在18个月时通过眼底自发荧光(FAF)结合频域光学相干断层扫描(SDOCT)进行分级。
  • CNV病灶通过荧光素血管造影(FA)手动分级,包括经典和隐秘CNV成分。
  • FAF和FA图像配准以量化CNV与MA重叠的面积和位置。

主要发现

  • 26眼在18个月时有MA且基线有CNV,其中84.6%眼显示MA与CNV重叠。
  • MA出现在对应基线经典CNV区域者占36.4%,隐秘CNV区域者占40.9%,两者均有着占22.7%,隐秘CNV区域MA面积(AMA)大于经典CNV区域。
  • 基线MA位于经典CNV区域者占76.9%,隐秘CNV区域者占61.5%,两者均有者占15.4%,隐秘CNV区域AMA大于经典CNV区域。
  • 在基线和18个月均有MA和CNV但无重叠的眼中,50%进展至累及基线CNV区域。
  • 6眼基线无MA但在18个月时于基线CNV区域内新发MA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To quantify the extent of topographic correspondence between baseline (BSL) choroidal neovascularization (CNV) and macular atrophy (MA) at follow-up in eyes with neovascular age-related macular degeneration (NVAMD). DESIGN: Post hoc analysis of randomized controlled clinical trial data. METHODS: Sixty treatment-naïve NVAMD patients from the TREX-AMD trial were followed for 18 months. Regions of month 18 macular atrophy (MA) were graded on fundus autofluorescence (FAF) with guidance of spectral-domain optical coherence tomography (SDOCT). CNV lesions were graded manually on fluorescein angiography (FA) with lesion components including classic and occult CNV delineated. FAF and FA images were registered to quantitate area and location of overlap between CNV and MA. Outcome measures included overlap of month 18 MA to BSL CNV subtype and progression of MA from BSL to month 18. RESULTS: Twenty-six eyes had both MA at month 18 and CNV at BSL. A total of 84.6% of eyes showed evidence of MA and CNV overlap. MA appeared by month 18 in regions corresponding to BSL classic CNV in 36.4% of eyes and occult CNV in 40.9%, and in both regions in 22.7%, with more area of MA (AMA) in regions of occult than classic CNV. MA position at BSL corresponded to BSL classic CNV in 76.9% of eyes and occult CNV in 61.5%, and to both regions in 15.4%, with more AMA in regions of occult than classic CNV. Among eyes with MA and CNV at BSL but with no overlap, 50% progressed to involve regions with BS -CNV. Six eyes had no BSL MA but developed MA at month 18 within regions of BSL CNV. CONCLUSIONS: In ranibizumab-treated eyes with NVAMD, more MA lesions develop within the region of baseline CNV (type 1, CNV-based MA) than outside (type 2, CNV-independent MA). Baseline-MA also tends to be located within regions of CNV in the pretreatment phase.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Abdelfattah NS, Hariri AH, Al-Sheikh M, et al. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. Am J Ophthalmol. 2018. PMID: 29763612. doi:10.1016/j.ajo.2018.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。